Robert M. Janosky
Corporate Officer/Principal bij SATSUMA PHARMACEUTICALS, INC.
Profiel
Robert M.
Janosky is currently the Chief Commercial Officer at Satsuma Pharmaceuticals, Inc. Prior to this, he worked as the VP of Business Development & Strategic Planning at DURECT Corp.
from 2016 to 2020.
He received his undergraduate degree from the University of Vermont and his MBA from the University of Rochester Simon Business School.
Actieve functies van Robert M. Janosky
| Bedrijven | Functie | Begin |
|---|---|---|
| SATSUMA PHARMACEUTICALS, INC. | Corporate Officer/Principal | 05-03-2020 |
Eerdere bekende functies van Robert M. Janosky
| Bedrijven | Functie | Einde |
|---|---|---|
| DURECT CORPORATION | Corporate Officer/Principal | 01-03-2020 |
Opleiding van Robert M. Janosky
| University of Vermont | Undergraduate Degree |
| University of Rochester Simon Business School | Masters Business Admin |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 1 |
|---|---|
| DURECT CORPORATION | Health Technology |
| Bedrijven in privébezit | 1 |
|---|---|
Satsuma Pharmaceuticals, Inc.
 Satsuma Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Satsuma Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. It develops novel therapeutic products for the acute treatment of migraines. Its product candidate, STS101, is a drug-device combination of a proprietary dry-powder formulation of dihydroergotamine mesylate, or DHE, which is designed to be self-administered with a proprietary pre-filled, single-use, nasal delivery device. The company was founded by John Kollins on June 21, 2016 and is headquartered in Durham, NC. | Health Technology |
